UC Irvine Health

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions

• Lung cancer5 trials
• Pancreatic cancer4 trials
• Bladder cancer3 trials
• Colorectal cancer3 trials
• Multiple myeloma3 trials
• Acute myeloid leukaemia2 trials
• Endometrial cancer2 trials
• Follicular lymphoma2 trials
• Mesothelioma2 trials
• Aortic stenosis1 trial
• Cervical cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• and 12 more

Phase

• Phase 1/26 trials
• Phase 26 trials
• Phase 36 trials
• Phase 13 trials
• Phase 2/31 trial
• Phase 41 trial

Status

• Recruiting14 trials
• Active, not recruiting3 trials
• Completed3 trials
• Enrolling by invitation2 trials
• Terminated2 trials
• Withdrawn1 trial

Lead sponsor

• Pfizer4 trials
• Gilead Sciences2 trials
• Regeneron Pharmaceuticals2 trials
• Revolution Medicines, Inc.2 trials
• AccurKardia, Inc.1 trial
• and 14 more

Running trials

• Enrolling by invitation

  ECG-based AI Screening for Cases of Undiagnosed Moderate-to-Severe Aortic Stenosis in the Primary Care Setting

  NCT07827105· AccurKardia, Inc.· Source

• Recruiting

  Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

  NCT07326566· Phase 2· Black Diamond Therapeutics, Inc.· Source

  Contact: Manisha Dandekar

• Recruiting

  A 2-part Phase 1/2 Open-label Trial on ODM-212

  NCT07563738· Phase 1/2· Orion Corporation, Orion Pharma· Source

  Contact: Farshid Dayyani

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Pfizer· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· Phase 3· Revolution Medicines, Inc.· Source

  Contact: Revolution Medicines Study Director

• Recruiting

  A Study of VET3-TGI in Patients With Solid Tumors

  NCT06444815· Phase 1· KaliVir Immunotherapeutics· Source

  Contact: Edward Uchio, MD (principal investigator)

• Recruiting

  Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

  NCT06375044· Phase 1· Jiangsu Simcere Pharmaceutical Co., Ltd.· Source

  Contact: Polina Bellman, MD (principal investigator)

• Recruiting

  A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)

  NCT06163430· Phase 1/2· Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source

  Contact: Toll Free Number

• Recruiting

  Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  NCT06056830· Phase 3· Clarity Pharmaceuticals Ltd· Source

  Contact: Edward Uchio, MD, FACS, CPI (principal investigator)

• Active, not recruiting

  A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

  NCT05828511· Phase 1/2· Regeneron Pharmaceuticals· Source

• Recruiting

  Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

  NCT06128551· Phase 1/2· Revolution Medicines, Inc.· Source

  Contact: Revolution Medicines, Inc.

• Recruiting

  Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

  NCT06057402· Phase 4· Pfizer· Source

• Recruiting

  AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

  NCT05602363· Phase 1· Carna Biosciences, Inc.· Source

  Contact: Catherine Coombs, MD

• Enrolling by invitation

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Active, not recruiting

  BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma

  NCT05322590· Phase 1/2· Bexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

  NCT05186974· Phase 2· Gilead Sciences· Source

• Recruiting

  A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  NCT04879329· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Recruiting

  Pancreatic Cancer Early Detection Consortium

  NCT04970056· Arbor Research Collaborative for Health· Source

  Contact: Blake Johnson

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Pancreatic cancer4 recruiting
• Bladder cancer3 recruiting
• Colorectal cancer2 recruiting
• Mesothelioma2 recruiting
• Multiple myeloma2 recruiting
• Aortic stenosis1 recruiting
• Cervical cancer1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Endometrial cancer1 recruiting
• Epilepsy1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Glioblastoma1 recruiting
• Head and neck cancer1 recruiting
• Kidney cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Melanoma1 recruiting
• Ovarian cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Recruiting

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· Phase 3· Regeneron Pharmaceuticals· Source

  Contact: Clinical Trials Administrator

• Terminated

  Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL

  NCT05883449· Phase 2· Affimed GmbH· Source

• Recruiting

  A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  NCT05548296· Phase 2· Acrivon Therapeutics· Source

  Contact: Mansoor Raza Mirza, MD

• Completed

  A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises

  NCT04935879· Phase 3· Pfizer· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Completed

  Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  NCT03836209· Phase 2· PrECOG, LLC.· Source